CLINICAL TRIALS PROFILE FOR MIRCERA
✉ Email this page to a colleague
All Clinical Trials for MIRCERA
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00048035 ↗ | A Study of Intravenous (iv) Mircera in Hemodialysis Patients With Chronic Renal Anemia | Completed | Hoffmann-La Roche | Phase 2 | 2002-03-01 | This study will determine the appropriate dose and frequency of administration of iv Mircera maintenance therapy in hemodialysis patients with chronic renal anemia who were previously receiving iv epoetin. The anticipated time on study treatment is 3-12 months and the target sample size is <100 individuals. |
| NCT00048048 ↗ | A Study of Mircera in Anemic Patients With Chronic Kidney Disease Not Yet on Dialysis. | Completed | Hoffmann-La Roche | Phase 2 | 2002-03-01 | This study will evaluate the efficacy and safety of different subcutaneous starting doses and dosing frequencies of Mircera in anemic patients with chronic kidney disease not yet on dialysis. The anticipated time on study treatment is 3-12 months and the target sample size is <100 individuals. |
| NCT00077597 ↗ | A Study of Mircera for the Treatment of Anemia in Dialysis Patients | Completed | Hoffmann-La Roche | Phase 3 | 2004-02-01 | This study will assess the efficacy and safety of Mircera given intravenously in the treatment of renal anemia in chronic kidney disease patients on dialysis who are not currently receiving epoetin or any other erythropoietic substance. The anticipated time on study treatment is 1-2 years and the target sample size is 100-500 individuals. |
| NCT00077610 ↗ | A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients | Completed | Hoffmann-La Roche | Phase 3 | 2004-02-01 | This study will assess the efficacy and safety of intravenous Mircera, given as maintenance treatment for renal anemia in chronic kidney disease patients on dialysis who were previously receiving iv epoetin. The anticipated time on study treatment is 1-2 years and the target sample size is 100-500 individuals. |
| NCT00077623 ↗ | A Study of Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients. | Completed | Hoffmann-La Roche | Phase 3 | 2004-03-01 | This study will assess the efficacy and safety of subcutaneous (sc) Mircera given as maintenance treatment for renal anemia in chronic kidney disease patients on dialysis who were previously receiving sc epoetin. The anticipated time on study treatment is 1-2 years and the target sample size is 100-500 individuals. |
| NCT00077766 ↗ | A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients. | Completed | Hoffmann-La Roche | Phase 3 | 2004-03-01 | This study will assess the efficacy and safety of intravenous (iv) Mircera given as maintenance treatment for renal anemia in chronic kidney disease patients on dialysis who were previously receiving iv darbepoetin alfa. The anticipated time on study treatment is 1-2 years and the target sample size is 100-500 individuals. |
| NCT00081471 ↗ | A Study of Mircera in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis | Completed | Hoffmann-La Roche | Phase 3 | 2004-06-01 | This study will assess the efficacy and safety of subcutaneous Mircera in the treatment of renal anemia in patients with chronic kidney disease who are not on dialysis and not receiving epoetin or any other erythropoietic substance. The anticipated time on study treatment is 1-2 years and the target sample size is 100-500 individuals. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for MIRCERA
Condition Name
Clinical Trial Locations for MIRCERA
Trials by Country
Clinical Trial Progress for MIRCERA
Clinical Trial Phase
Clinical Trial Sponsors for MIRCERA
Sponsor Name
